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Abstract
Background: The human APOBEC protein family plays critical but distinct roles in host defense. Recent studies
revealed that APOBECs mediate C-to-T mutagenesis in multiple cancers, including breast cancer. It is still unclear
whether APOBEC gene family shows functional diversification involved in cancer mutagenesis.
Results: We performed an integrated analysis to characterize the functional diversification of APOBEC gene family
associated with breast cancer mutagenesis relative to estrogen receptor (ER) status. Among the APOBEC family, we
found that both APOBEC3B and APOBEC3C mRNA levels were significantly higher in estrogen receptor negative (ER−)
subtype compared with estrogen receptor positive (ER+) subtype (P < 2.2 × 10−16 and P < 3.1 × 10−5, respectively).
Epigenomic data further reflected the distinct chromatin states of APOBEC3B and APOBEC3C relative to ER status.
Notably, we observed the significantly positive correlation between the APOBEC3B-mediated mutagenesis and
APOBEC3B expression levels in ER+ cancers but not in ER− cancers. In contrast, we discovered the negative
correlation of APOBEC3C mRNA levels with base-substitution mutations in ER− tumors. Meanwhile, we observed
that breast cancers in carriers of germline deletion of APOBEC3B gene harbor similar mutation patterns, but higher
mutation rates in the TCW motif (W corresponds to A or T) than cancers in non-carriers, indicating additional factors
may also induce carcinogenic mutagenesis.
Conclusions: These results suggest that functional potential of APOBEC3B and APOBEC3C involved in cancer
mutagenesis is associated with ER status.
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Background
In the human genome, APOBEC family comprises of
a total of 11 genes. They have been known to encode
Zn2+-dependent DNA cytosine deaminases. Of these
11 members, seven apolipoprotein B mRNA editing en-
zyme, catalytic polypeptide-like 3 genes (APOBEC3A,
APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOB
EC3G, and APOBEC3H) are tandemly distributed on
chromosome 22 [1]. The other four members are located
on other chromosomes, including APOBEC1, APOBEC2,
APOBEC4, and activation-induced cytidine deaminase
(AICDA). The APOBEC family proteins show different
classes of DNA cytosine deaminase domains and distinct
tissue expression profiles [2–5], indicating they may have
diverse biological functions. For example, the APOBEC
proteins exhibit different activities in restricting virus repli-
cation and inhibiting LINE-1 retrotransposition [6–8].
Recent studies showed the elevated expression of
APOBEC3B in multiple tumors [9–12]. Meanwhile, the
strong correlation of somatic base-substitution mutation
with APOBEC3B mRNA levels in cancer samples has
implicated APOBEC3B as an enzymatic source inducing
the C-to-T somatic mutations [9, 10, 13, 14]. However,
in breast cancer subtypes, the distinct mutational pat-
terns and genomic changes have also been reported
[15–18], meaning that the APOBEC-mediated muta-
genesis and APOBEC family expression may be variable
in cancer subtypes [14].
Thanks to two projects, The Cancer Genome Atlas
(TCGA) [17] and the Encyclopedia of DNA Elements
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(ENCODE) project [19], leveraging these diverse types of
data to interpret functional features of genes or gene
families in particular cancer types is possible. Here, we
performed integrated analysis on diverse high-throughput
sequencing data involved in somatic mutation, gene ex-
pression, and epigenetic profiles. The aim of this study is
to investigate the functional diversification of the APOBEC
family genes in breast cancer, in cancer subtypes with a
focus on estrogen receptor (ER) status.
Results
Data summary
For breast cell lines, a total of 42 high-throughput se-
quencing data, including 10 RNA sequencing (RNA-seq)
data from two data sets [20, 21], 18 ChIP sequencing
(ChIP-seq) data, 4 corresponding input DNA (control)
from five data sets, and 10 bisulfite sequencing (BS-seq)
data from two data sets [19–22], were collected in this
study (Additional file 1: Table S1). Among ten RNA-seq
data, eight are from breast cancer cell lines and two are
from normal breast cell lines.
Of the 18 ChIP-seq datasets, six histone modifications,
including histone H3 lysine 4 methylations (H3K4me1,
H3K4me3), lysine 9 trimethylation (H3K9me3), lysine 27
trimethylation (H3K27me3), lysine 36 trimethylation
(H3K36me3), and histone H3 lysine 27 acetylations
(H3K27ac), were conducted in each of the HCC1954
cell line, an estrogen receptor negative (ER−) breast
cancer cell line, MCF-7 cell line, an estrogen receptor
positive (ER+) breast cancer cell line, and human mam-
mary epithelial cells (HMEC), a normal breast cell line.
For the ten bisulfite-seq datasets, two included whole-
genome BS-seq at the single nucleotide resolution in the
ER− breast cancer cell line HCC1954 and the normal
cell line HMEC [20]. Eight were generated by reduced
representation bisulfite sequencing (RRBS) in low depth
[21]. As no or low sequencing coverage in the proximal
promoters of APOBECs in the initial analysis, we dis-
carded these eight RRBS data for further analyses.
RNA-seq data was available for 1000 breast tissue
specimens from TCGA database, including 915 breast
carcinoma samples and 85 adjacent normal breast tis-
sues (Table 1). Among 915 breast tumor samples, 664,
196, and 55 are from breast tumor patients with ER+,
ER−, and unknown ER status, respectively.
Expression profiling of APOBECs in breast cancer
We quantified mRNA levels for each of the 11 APOBEC
family members in ten breast cell lines including cancer
and normal cell types (Additional file 1: Table S2). Con-
sistent with the previous findings [9], only APOBEC3B
shows the over-expression in the range of two- to four-
fold changes in breast cancer cells relative to normal
cells. Other APOBEC family members have no or very
low expression levels in normal or cancer cells with an
exception of APOBEC3C, whose expression levels are
highest in normal cells and decline slightly in the ER−
cancer cell lines, but drop sharply in the ER+ cancer cell
lines (Fig. 1a). Relative to ER− cancer cell lines, these re-
sults show the down-regulation of both the APOBEC3B
and APOBEC3C genes in ER+ cancer cells.
We then expanded this analysis to include a total of
1000 RNA-seq data from TCGA project. In agreement
with observation in cancer cell lines, both the APOB
EC3B and APOBEC3C genes show higher expression
levels in ER− cancers (P < 2.2 × 10−16 and P < 3.1 × 10−5,
respectively, two-sided Wilcoxon rank sum test) relative
to ER+ cancers (Fig. 1b). For other APOBEC family
members (Additional file 2: Figure S1), they show either
extremely low (median log2-transformed RPKM< 0)
Table 1 Summary of breast cell lines and tissue specimens in the study
Breast non-tumor cell lines Breast cancer cell lines Breast tumor tissues Adjacent normal breast tissues
No. of samples 2 8 915 85
ER status
ER+ 0 4 (50 %) 664 (72.6 %) 67 (78.9 %)
ER− 2 (100 %) 4 (50 %) 196 (21.4 %) 15 (17.6 %)
Unknown 0 0 55 (6.0 %) 3 (3.5 %)
CNV
CN0 na na 28 (3.1 %) 2 (2.4 %)
CN1 na na 162 (17.7 %) 17 (20 %)
CN2 na na 597 (65.2 %) 66 (77.6 %)
Unknown na na 128 (14.0 %) 0
Availablity of exome-seq data
Yes na na 750 (82.0 %) na
No na na 165 (18.0 %) na
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mRNA levels (including APOBEC3A, APOBEC3H,
APOBEC1, APOBEC2, APOBEC4, and AICDA), or no
obvious expression differences between ER+ and ER−
breast cancers (including APOBEC3D, APOBEC3F,
and APOBEC3G). Additionally, the expression levels
of APOBEC family genes in 55 breast cancer tissues
with unknown ER status are similar with those
samples of ER+ subtypes, indicating many of these 55
patients probably belong to ER+ subtype. These re-
sults together indicate that the expression patterns of
APOBEC3B and APOBEC3C genes may be associated
with ER status.
Chromatin states of APOBEC gene family in
breast cancer cells
To investigate whether the different expression profiles of
APOBEC family members could show different chromatin
states in relation to ER status, we integrated ChIP-seq data
for six histone modifications, including H3K4me3 and
H3K36me3 (two epigenetic markers connected with
gene activity) [23, 24], H3K27ac and H3K4me1 (two
enhancer-associated hallmarks) [25, 26], and H3K9me3
and H3K27me3 (two typical epigenetic markers indica-
tive of transcriptional repression and heterochromatin
formation) [23, 27], across three breast tissue relevant
cell types: ER+ (MCF-7), ER− (HCC1954) breast cancer
cells, and normal mammary epithelial cells (HMEC).
Notably, in the ER− cell line HCC1954, we observed ac-
tive promoter and clustered enhancers surrounding
both the APOBEC3B and APOBEC3C loci (Fig. 1c).
Meanwhile, these two genes show strong transcription
signal. In addition, parts of active promoters or en-
hancers at the APOBEC3F and APOBEC3G genes were
also found. For the other APOBEC family genes, we did
Fig. 1 Expression of APOBEC3B and APOBEC3C genes in breast cancer cell lines and tissues in relation to ER status. a mRNA levels of APOBEC3B
and APOBEC3C in breast cancer cell lines with ER subtypes and normal cell lines. b mRNA levels of APOBEC3B and APOBEC3C in breast tumor
tissues with ER subtypes and adjacent normal tissues. c Comparison of chromatin states in APOBEC3 family genes in ER+ (MCF-7), ER− (HCC1954)
breast cancer cells, and normal cells (HMEC). The highlight with rectangle is on APOBEC3B and APOBEC3C genes. Chromatin states characterized
by the ChromHMM algorithm are represented by different colors shown in the bottom
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not observe active promoter or enhancers (Additional
file 2: Figure S2).
In contrast, in the ER+ cancer cell line MCF-7, we only
observed promoter (Fig. 1c) activity at the APOBEC3B,
but not at the APOBEC3C and the other APOBEC family
genes (Additional file 2: Figure S2). Furthermore, com-
pared with the normal HMECs, the loss of promoter
activity at the APOBEC3C, APOBEC3F, and APOBEC3G
genes was specifically detected in the ER+ cancer cell
(Fig. 1c). The observed chromatin state profiles of the
APOBEC family genes are quite concordant with the gene
expression patterns, further suggesting that the functional
divergence of the APOBEC3B and APOBEC3C genes may
be related to the ER status.
In addition, with respect to several APOBEC family
members (including APOBEC3A, APOBEC3H, APOBEC1,
APOBEC2, APOBEC4, and AICDA) showing no or
extremely low expression levels in both ER+ and ER−
breast cancers, we did not find any enrichment of
repressive chromatin modifications (H3K9me3 and
H3K27me3) in these genes (Fig. 1c and Additional file 2:
Figure S2), suggesting some additional molecular
mechanisms probably participate in the regulation of
these genes.
DNA methylation of APOBECs in breast cancer cells
DNA methylation at the proximal promoter of genes is
well-characterized as an epigenetically repressive marker
[28, 29]. We further analyzed the DNA methylation pro-
files of APOBECs using BS-seq data to detect methyla-
tion signatures. Due to unavailability of whole-genome
BS-seq data for ER+ cancer cells, we could not conduct
the comparative DNA methylation analysis between ER+
and ER− cancer cells. Here, we only compared the DNA
methylation levels of APOBECs between the ER− breast
cancer cells and normal cells (Fig. 2a, b). As expected,
highly expressed genes possess low DNA methylation
levels in their proximal transcription start site (TSS) re-
gions (defined as ± 0.5 kb of TSS). For example, APO-
BEC3B and APOBEC3C show low DNA methylation
levels (median methylation ratio ≤20 %) in both HMEC
and ER− breast cancer cells, although a slight increase in
ER− cancer cells (Fig. 2c). While for other APOBEC mem-
bers, including APOBEC3D, APOBEC3F, and APOBEC3G,
they show DNA hyper-methylation in ER− breast cancer
cells when compared to HMEC (P < 0.01, Wilcoxon signed
rank test). In addition, except the APOBEC3H gene, we
found high DNA methylation levels of the remaining
APOBEC members, including APOBEC1, APOBEC2,
APOBEC3A, APOBEC4, and AICDA, in both HMEC
and ER− breast cancer cells (Fig. 2c). Together, these
findings are in agreement with the observation from
the gene expression data.
Clinical outcome with mRNA levels of APOBECs
We then assessed whether the mRNA levels of both
APOBEC3B and APOBEC3C genes were associated
with clinical outcome. Compared to patients who are
deceased, surviving patients show lower expression
levels of APOBEC3B and higher expression levels of
APOBEC3C (Fig. 3a). Meanwhile, a similar trend was
observed for TNM stage, with higher APOBEC3B (Fig. 3b)
and lower APOBEC3C (Fig. 3c) mRNA level associated
with advanced breast cancer stage. However, no associ-
ation was observed between the APOBEC3B and APO-
BEC3C mRNA levels with survival times (Additional
file 2: Figure S3).
APOBEC-mediated mutagenesis in relation to ER status
We examined whether the correlation between APOBEC-
mediated mutagenesis and expression levels of APOBEC
family genes would be associated with ER status. A total
of 46,096 somatic single nucleotide variants (SNVs)
(57.9 ± 50.9, mean ± SD, Additional file 2: Figure S4A)
from 750 exome-sequencing (exome-seq) data and
matched RNA-seq data were combined to conduct such
test. Among these somatic SNVs, 21,339 are C>T/G>A
mutations (27.1 ± 24.8, mean ± SD, Additional file 2:
Figure S4B). Interestingly, the significantly positive cor-
relation between the number of C>T/G>A mutations
per tumor exome and APOBEC3B mRNA levels is ob-
served in ER+ cancers (ρ = 0.32, P = 7.09 × 10−15), but
not in ER− cancers (ρ = 0.04, P = 0.60, Fig. 4a). Locally
weighted polynomial regression also shows a similar
trend. Conversely, we found a significantly negative
correlation between the total number of C>T/G>A mu-
tations per tumor exome and APOBEC3C mRNA levels
in ER− cancers (ρ = −0.26, P = 0.001), which is also
supported by the locally weighted regression (Fig. 4b).
However, the negative correlation for APOBEC3C is
not obvious in ER+ cancers. Similar observations exist
for both APOBEC3B and APOBEC3C when including
all somatic mutations (Additional file 2: Figure S5).
APOBEC-mediated mutagenesis in relation to germline
deletion of APOBEC3B
In the analysis of the CNV status of APOBEC3B [30]
in 787 breast tumor samples, we detected 190 breast
cancer samples in carriers of germline deletion of
APOBEC3B gene. Among them, 28 (75 % being ER+)
and 162 (80 % being ER+) samples bear homozygous
(zero copy, CN0) and heterozygous (one copy, CN1)
deletions, respectively. Among the CN2 group (wild-
type), 74 % of them are ER+. Figure 5a shows that the
group with CN0 (homozygous deletion) effectively
eliminates the transcription of APOBEC3B, and the
CN1 group reduced mRNA level of APOBEC3B, com-
pared to the CN2 group, indicating the high confidence of
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CNV calling in this study. We then examined the possi-
bility of functional interaction between APOBEC3B and
other APOBEC family members. In cancer samples
with the depletion of APOBEC3B, although the expres-
sion level of the APOBEC3A is decreased, such change
is likely a false positive as reported by Leonard et al.
[13]. The mRNA levels for other APOBEC family
members do not exhibit the remarkable alteration
(Additional file 2: Figure S6), including the APOBEC3C
gene (Fig. 5a), further raising the possibility that there
are less functionally direct interactions between APOBEC
family members, at least between APOBEC3B and other
members.
To address whether the APOBEC-mediated muta-
genesis in breast tumors is directly induced by the
APOBEC3B protein, stratified by CNV of APOBEC3B
locus, we further compared the number of mutations
per tumor exome in breast cancer tissues. The results
show the remarkably positive correlation (r = 0.33, P =
8.9 × 10−16) between the number of SNVs per exome
and APOBEC3B expression levels for APOBEC3B with
CN2, but not for CN1 and CN0 types (Fig. 5b). Similar
Fig. 2 DNA methylation of APOBECs in breast cancer cells. Heatmap of DNA methylation levels per 100 bp bin within ±5 kb regions of APOBEC
gene family transcription start sites (TSS) in HCC1954 ER− breast cancer cells (a) and HMEC normal breast cells (b). The color bar shown represents the
DNA methylation ratio from the lowest (green) to the highest (red). c Boxplot of DNA methylation levels of APOBECs in breast cancer and normal cells
in the proximal regions (defined as ±0.5 kb of TSS)
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but negative correlation of mutations per exome with
APOBEC3C expression levels is observed. Meanwhile,
the comparative results show that the number of
somatic SNVs in the absence of APOBEC3B (CN0) is
not significantly different with the other two genotypes
(CN1 and CN2, Fig. 5c), although some biases could
be introduced in the comparison, including the un-
equal sample size and regional (not whole-genome)
variants for three genotypes. Furthermore, in terms of
mutation types, the mutation patterns are quite similar
with predominance of C-T transition for all three
APOBEC3B genotypes (Fig. 5d). Compared with sam-
ples with CN1 and CN2 of APOBEC3B, we observed
elevated frequency of C-G mutation in samples con-
taining the CN0 of APOBEC3B (Fig. 5d). The excessive
analysis of trinucleotide motifs with centered C>A,
C>G, and C>T mutation types shows a significantly in-
creased TCW motif occurrence in CN0 group (where
W corresponds to A or T, Fig. 5e) compared with CN1
(P = 2.4 × 10−4) and CN2 groups (P < 2.2 × 10−16) based
on Fisher’s exact test.
Discussion
In this study, we investigated the genomic, transcrip-
tomic, and epigenetic regulation of APOBEC gene family
in breast cancers by integrating diverse high-throughput
sequencing data. The transcriptome data from both
breast cancer cell lines and tumor specimens reveal that
the APOBEC3B and APOBEC3C genes show significant
differences at the transcription levels between ER+ and
ER− breast tumors. On the one hand, we recapitulated
previous findings that the up-regulation of APOBEC3B
gene represents a growing enzyme-catalyzed cytosine-
to-uracil deamination activity in carcinogenesis [9, 10].
On the other hand, the substantial up-regulation of
APOBEC3B gene and absence of down-regulation of
APOBEC3C gene in ER− subtypes suggest that the
cytosine deaminase activity for APOBECs may be dis-
tinct in cancer subtypes. Furthermore, our study also
suggests that the APOBEC-induced cancer mutagenesis
is distinct regarding ER status, in agreement with the
phenomena of different mutational spectrum observed
between ER+ and ER− breast cancers [15].
Our results provide an additional support of the
functional significance of APOBEC3B and probably
APOBEC3C in breast carcinogenesis [12]. Based on the
overall similar mutation patterns between breast cancers
Fig. 3 Association of clinical outcome with expression levels of
APOBEC3B and APOBEC3C. a Expression levels of APOBEC3B and
APOBEC3C in breast cancer patients who are alive or not. b and c
Association of mRNA levels of APOBEC3B and APOBEC3C with
breast tumor stages ranging from I to IV
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in carriers of germline deletion of APOBEC3B genes and
non-carriers, and a higher occurrence of somatic muta-
tions on the TCW motif in APOBEC3B deletion samples,
we speculate that germline deletion of APOBEC3B, ex-
pression of APOBEC3B and APOBEC3C, and somatic mu-
tation may interact in contributing to breast cancer.
Integrated analysis of functional genomic data is a
powerful approach with broad applications in many
areas, including prediction of gene activity [31] and
annotation of non-coding RNAs [32]. Using a similar
approach, our integrated analyses illuminate the differ-
ence of chromatin states among APOBECs in breast
cancer subtypes, which is highly consistent with the
gene expression data. For instance, the active promoter
and enhancer states at the APOBEC3B gene are con-
cordant with the over-expression of APOBEC3B, par-
ticularly in ER− subtype. Meanwhile, the loss of active
promoter and enhancer signals at the APOBEC3C gene
in the ER+ cancer cell reflects the down-regulation of
this gene observed in the ER+ subtype. In addition, the
DNA hypermethylation may explain no or low expres-
sion profiles of other APOBECs. These results are con-
cordant with Isobe’s report [33, 34] in blood cells.
Meanwhile, Pauklin et al. [35] have reported the estro-
gen induced increase of APOBEC3B gene expression by
nearly 1.5-fold in a dose-dependent manner, but not
APOBEC3C gene and other members in human MCF-7
cells, suggesting the possibility that ER may directly (or
indirectly) regulate APOBECs in breast cancer cells
through recruiting chromatin modifiers [36].
Compared with APOBEC3B, the APOBEC3C gene may
play a different role in the cancer genome mutagenesis.
For example, we observed that the elevated expression
levels of APOBEC3C but lowered expression levels of
APOBEC3B in breast cancer patients have better clinical
outcomes. The opposite correlation of APOBEC3B and
APOBEC3C genes’ expression with clinical outcomes fur-
ther provides a possibility of using both two genes as po-
tential biomarkers in prognosis. Although no functional
assays are performed in this study, several lines of
Fig. 4 Relationship between mRNA levels of APOBEC3B (a) and APOBEC3C (b) and number of C>T/G>A per tumor exome stratified by the ER status.
The black lines and red curves are drawn from the linear regression model and local regression smoothing, respectively
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Fig. 5 (See legend on next page.)
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evidence support the possible functionality of the
APOBEC3C protein in breast cancer.
First, APOBEC3C is localized in both the cytoplas-
mic and nuclear compartments, which is not only ob-
served in human cells [37–39], but also observed in
the rhesus counterparts [7], suggesting functionally
constrained localization of APOBEC3C. However, for
other APOBECs, they show either tissue-restricted ex-
pression patterns (APOBEC3A, APOBEC1, APOBEC2,
APOBEC4, and AICDA) or cytoplasmic localization
(APOBEC3D, APOBEC3F, APOBEC3G, and APO-
BEC3H) in human cells [3, 4, 6, 7, 10, 39, 40]. Along
with high expression levels of APOBEC3C gene in ER−
breast cancer cells, it is possible that both APOBEC3B
and APOBEC3C retain DNA cytosine deaminase activity
in breast cancer. Meanwhile, Lackey et al. reported
that throughout mitosis in HEK293T and HeLa cells,
APOBEC3C has access to genomic DNA during inter-
phase and telophase, while APOBEC3B is excluded
from the genomic DNA during mitosis [37]. Such phe-
nomena are consistent with our findings that there is
less functional interaction between APOBEC3C and
APOBEC3B proteins, suggesting they may perform dif-
ferent roles in cancer cells.
Second, given that the APOBEC3C possesses a single
active Z2-cytosine deaminase domain, while the APO-
BEC3B has double Z-coordinating (Z1 and Z2) deami-
nase domains [8, 41], the crystal structure determinants
and functional comparison have revealed the distinct
substrate preferences for binding HIV-1 DNA between
the single- and double-domained APOBEC3 enzymes
[42–44], raising the possibility that these two enzymes
have differential DNA binding specificity which might
help explain the relative differences in their observed
mutagenesis in breast cancer cells, especially in the ER−
cancers.
Third, besides the deaminase activity for APOBECs,
the APOBEC3 family proteins also contribute to inhibit
the L1 retrotransposition in a deaminase independent
manner [6, 38, 45]. For instance, depletion of APO-
BEC3C significantly increases the L1 retrotransposition
activity by ~80 % in HeLa cells [39]. Meanwhile, many
studies have strongly indicated the enhanced activity of
LINE-1 retrotransposons in human cancers induces
genome instability, DNA damage, and genetic variation
[46–51], further implying the potentially functional roles
of APOBEC3C in breast cancer.
Conclusions
In conclusion, our integrated analyses suggested that
APOBEC3B and APOBEC3C expression patterns were
correlated with ER status and clinical outcome, pro-
viding an additional implication that these two genes
may contribute to mutation profile and clinical out-
come in breast cancer subtypes.
Methods
Data collection
We collected functional genomics data from experi-
ments including the following: (1) RNA-seq, (2) chroma-
tin immunoprecipitation followed by high-throughput
DNA sequencing (ChIP-seq), and (3) bisulfite sequen-
cing (BS-seq) data, for breast cell lines (including both
normal and cancer) from the Gene Expression Omnibus
(GEO) database [52] and ENCODE project. We initially
searched the GEO database using the following terms:
breast [AND] sequencing. After manual curation to rule
out data where cell lines were treated by additional che-
micals or siRNAs in experiments, all relevant data with
no redundancy were retained for further analyses. We
retrieved the ChIP-seq data released by the ENCODE
project for well-characterized chromatin modifications
in two breast cell lines: one normal cell line, called hu-
man mammary epithelial cells (HMEC), and the other
ER+ breast cancer cell line (MCF-7). We also down-
loaded a total of 1000 RNA-seq data with approval
(BAM files, Level 1) and corresponding clinical data
(Biotab format) for breast tissue specimens (including
915 cancer and 85 adjacent normal tissue specimens) from
TCGA (https://tcga-data.nci.nih.gov/tcga/). In addition,
we downloaded 840 CEL files (Affymetrix SNP 6.0 array,
level 1) and processed somatic mutation data (level 2)
from 776 whole exome-sequencing (exome-seq) for the
breast cancer from TCGA data portal, where 787 and 750
have matched RNA-seq data, respectively.
Data processing and statistics
All raw sequencing data (FASTQ format) were initially
mapped to the human reference genome (hg19) using
Bowtie2 program [53] with the default setting. Aligned
(See figure on previous page.)
Fig. 5 Gene expression and somatic mutation signatures in breast tumors stratified by copy numbers of APOBEC3B gene. a Boxplot of mRNA levels of
APOBEC3B and APOBEC3C in totally 787 breast tumors. b Relationship between APOBEC3B (upper panel) and APOBEC3C (lower panel) expression levels and
number of somatic SNVs per tumor exome. The red curves are drawn from the local regression smoothing. c Boxplot of the total number of somatic
mutations per tumor exome (y-axis, log10 scaled). The color bars shown in the right are the original number of somatic SNVs per exome. d Frequency of
each of six somatic mutation types. e Excess rate of trinucleotide motifs with centered C>A, C>G, and C>T mutations shown from left to right panels. The
excess rate is calculated by (observed occurrence −mean occurrence) / mean occurrence. CN0, CN1, and CN2 present the zero, one, and two copies of
APOBEC3B gene, respectively
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data in SAM format were processed and converted into
BAM files using SAMtools program [54]. As each type
of sequencing data conveys specifically biological pur-
pose, we used the following methods to process the cor-
responding sequencing data. Except relevant programs
described, all other bioinformatics analyses were imple-
mented using Perl and R programming.
For RNA-seq data, we used similar methods described
elsewhere [55]. In brief, to characterize the quantitative
expression of each RefSeq gene, the reads per kilobase
and million mapped reads (RPKM) was calculated as the
number of mapped reads with the mapping quality
(MAQ) ≥30 aligning to each transcript multiplied by 1
million and divided by the length of the transcript times
the total number of aligned reads. Then the RPKM values
for APOBEC family members were extracted to quantify
their expression levels. The same method was also utilized
to process BAM files for TCGA RNA-seq data.
To uniformly analyze and visualize ChIP-seq data, we
used the MACS14 (version 1.4.2) algorithm [56] to call
peaks of ChIP-seq data for histone modifications
against the corresponding control data in 20 bp reso-
lution (−−space = 20) at P < 1 × 10−5. The resulting peak
files (.bed) were then implemented into the ChromHMM
algorithm [57] at a 200-bp resolution for chromatin state
characterization. We ran ChromHMM with a range of
possible states and settled on a 9 state model as it ac-
curately captured biologically meaningful patterns in a
reproducible way. The resulting genome segmentation
files were uploaded to the UCSC Genome Browser as a
custom track to visualize the chromatin sates and com-
parison among APOBEC family members.
For BS-seq data, we employed the BSMAP (version
2.74) program [58] to analyze DNA methylation ratios
on each CpG site. Each CpG site supported by ≥4 reads
was considered. To compare the DNA methylation ra-
tios among APOBECs, we calculated mean DNA
methylation levels within each 100-bp sliding window
across ±5 kb regions of transcription start site (TSS) for
each of APOBEC family members.
Level 1 CEL files for the breast cancer were used for
copy number variation (CNV) calling. CNVs were de-
tected based on the signal intensities of over 1.8 million
SNP or copy number probes on the Affymetrix SNP 6.0
array. The Affymetrix Power Tools (APT-1.14.3) package
was used to normalize for samples run on the same plate
according to file handles and the chemistry file available.
CNVs were called using Birdsuite (version 1.4) [59], which
calls both common and rare CNVs. The APOBEC3B dele-
tion is named as CNP2576 (hg19, chr22: 39363620–
39375307) in Canary and was determined by 24 probes. In
the present study, we only focus on this APOBEC3B de-
letion and copy number states of 0, 1, and 2 (CN0,
CN1, and CN2) were used. Genotypes were checked
against sample barcodes and participant IDs to identify
possible duplicate samples.
For somatic mutation data, both somatic single nu-
cleotide variants (SNVs) and C>T/G>A mutations per
tumor were first summed. The correlation between the
number of C>T/G>A mutations (or somatic SNVs) and
expression levels of APOBECs was calculated using non-
parametric Spearman’s Rank correlation statistics. The
same analysis was employed stratifying for APOBEC3B
germline deletion states. Six types of somatic SNVs
(C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/A>G,
T>G/A>C) were counted and their relative frequencies
were then calculated and compared. Following the
method reported in the previous study [10], we com-
pared the trinucleotides motif patterns with the back-
ground distribution normalized among breast cancer
samples in different copies of APOBEC3B gene.
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Additional file 1: Tables S1 and S2. Table S1. Data characteristics in
this study. Table S2. Expression levels of APOBEC family genes across ten
breast cell lines. (XLSX 14 kb)
Additional file 2: Figures S1–S6. Figure S1. Expression profiles of
APOBEC family genes in breast tumor tissues and adjacent normal tissues
in relation to ER status. Figure S2. Comparison of chromatin states in
APOBEC1 (A), APOBEC2 (B), APOBEC4 (C), and AICDA (D) genes in ER+
(MCF-7), ER− (HCC1954) breast cancer cells, and normal cells (HMEC).
Chromatin states characterized by the ChromHMM algorithm are represented
by different colors shown in the bottom. Figure S3. Kaplan-Meier curve for
overall survival of four patient groups with higher (top 50 %) or lower
(bottom 50 %) expression of APOBEC3B and APOBEC3C genes in breast
cancer. Figure S4. Distribution of the number of somatic mutations
(A) and C>T/G>A mutations (B) per tumor exome. The red curve is a
kernel density estimate. Figure S5. Relationship between mRNA levels
of APOBEC3B (upper panel) and APOBEC3C (lower panel) and number
of somatic SNVs per tumor exome stratified by the ER status. The black
lines and red curves are drawn from the linear regression model and
local regression smoothing, respectively. Figure S6. Expression profiles
of APOBEC family genes in breast tumor tissues in relation with copy
numbers of APOBEC3B. (ZIP 559 kb)
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